In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.

AUTOR(ES)

Sarubbi, F A

RESUMO

Cefpodoxime proxetil (U-76,252; CS-807) is a new esterified oral cephem antibiotic with a broad antibacterial spectrum. Since data regarding the activity of cefpodoxime against Branhamella catarrhalis are limited, we tested its activity against 200 B. catarrhalis isolates. The drug was highly active against beta-lactamase-negative and -positive isolates; 99% of all strains tested showed a cefpodoxime proxetil MIC of less than or equal to 2.0 micrograms/ml.

Documentos Relacionados

• In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae.
• In vitro activity of U-76,252 (CS-807), a new oral cephalosporin.
• Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807).
• In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis.
• Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis.